Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Genotype-phenotype correlations in pheochromocytoma and paraganglioma.

Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, Pacak K.

Endocr Relat Cancer. 2019 Mar 1. pii: ERC-19-0024.R2. doi: 10.1530/ERC-19-0024. [Epub ahead of print]

PMID:
30893643
2.

RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective.

Crona J, Backman S, Welin S, Taïeb D, Hellman P, Stålberg P, Skogseid B, Pacak K.

Cancers (Basel). 2018 Dec 15;10(12). pii: E518. doi: 10.3390/cancers10120518.

3.

Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.

Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V.

Scand J Gastroenterol. 2018 Dec;53(12):1509-1518. doi: 10.1080/00365521.2018.1531653. Epub 2018 Nov 19.

PMID:
30449217
4.

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms.

Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):26-36. doi: 10.1159/000494258. Epub 2018 Oct 3.

PMID:
30282083
5.

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).

Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):54-62. doi: 10.1159/000493318. Epub 2018 Aug 28.

6.

Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

Krauss T, Ferrara AM, Links TP, Wellner U, Bancos I, Kvachenyuk A, Villar Gómez de Las Heras K, Yukina MY, Petrov R, Bullivant G, von Duecker L, Jadhav S, Ploeckinger U, Welin S, Schalin-Jäntti C, Gimm O, Pfeifer M, Ngeow J, Hasse-Lazar K, Sansó G, Qi X, Ugurlu MU, Diaz RE, Wohllk N, Peczkowska M, Aberle J, Lourenço DM Jr, Pereira MAA, Fragoso MCBV, Hoff AO, Almeida MQ, Violante AHD, Quidute ARP, Zhang Z, Recasens M, Díaz LR, Kunavisarut T, Wannachalee T, Sirinvaravong S, Jonasch E, Grozinsky-Glasberg S, Fraenkel M, Beltsevich D, Egorov VI, Bausch D, Schott M, Tiling N, Pennelli G, Zschiedrich S, Därr R, Ruf J, Denecke T, Link KH, Zovato S, von Dobschuetz E, Yaremchuk S, Amthauer H, Makay Ö, Patocs A, Walz MK, Huber TB, Seufert J, Hellman P, Kim RH, Kuchinskaya E, Schiavi F, Malinoc A, Reisch N, Jarzab B, Barontini M, Januszewicz A, Shah N, Young WF Jr, Opocher G, Eng C, Neumann HPH, Bausch B.

Endocr Relat Cancer. 2018 Sep;25(9):783-793. doi: 10.1530/ERC-18-0100. Epub 2018 May 10.

PMID:
29748190
7.

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.

Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH.

Clin Ther. 2018 Jun;40(6):952-962.e2. doi: 10.1016/j.clinthera.2018.04.006. Epub 2018 May 1.

8.

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET.

Med Oncol. 2018 Mar 6;35(4):47. doi: 10.1007/s12032-018-1103-x.

9.

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.

Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988. doi: 10.1007/s00259-018-3945-z. Epub 2018 Mar 1.

10.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET.

PLoS One. 2017 Nov 7;12(11):e0187667. doi: 10.1371/journal.pone.0187667. eCollection 2017.

11.

Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.

Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, Öberg K, Hellman P, Norlén O, Stålberg P.

JAMA Oncol. 2018 Feb 1;4(2):183-189. doi: 10.1001/jamaoncol.2017.3326.

12.

[Swedish white paper on donation can give more donors without compromising ethics].

Welin S.

Lakartidningen. 2017 Jul 14;114. pii: EP6C. Swedish.

13.

A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.

Dumanski JP, Rasi C, Björklund P, Davies H, Ali AS, Grönberg M, Welin S, Sorbye H, Grønbæk H, Cunningham JL, Forsberg LA, Lind L, Ingelsson E, Stålberg P, Hellman P, Tiensuu Janson E.

Endocr Relat Cancer. 2017 Aug;24(8):427-443. doi: 10.1530/ERC-17-0196. Epub 2017 Jun 20.

14.

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers.

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 8. No abstract available.

15.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.

Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):196-200. doi: 10.1159/000457956. Epub 2017 Feb 11. No abstract available.

16.

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M.

J Clin Oncol. 2017 Jan;35(1):14-23. Epub 2016 Oct 28.

PMID:
27918724
17.

Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours.

Crona J, Norlén O, Antonodimitrakis P, Welin S, Stålberg P, Eriksson B.

J Clin Endocrinol Metab. 2016 Feb;101(2):445-52. doi: 10.1210/jc.2015-2436. Epub 2015 Dec 16.

PMID:
26672633
18.

Autism, Accommodation and Treatment: A Rejoinder to Chong-Ming Lim's Critique.

Jaarsma P, Welin S.

Bioethics. 2015 Nov;29(9):684-5. doi: 10.1111/bioe.12183. Epub 2015 Aug 26.

PMID:
26307242
19.

Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma.

Crona J, Ljungström V, Welin S, Walz MK, Hellman P, Björklund P.

PLoS One. 2015 Jul 31;10(7):e0133210. doi: 10.1371/journal.pone.0133210. eCollection 2015.

20.
21.

Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U.

Acta Oncol. 2014 Oct;53(10):1284-97. doi: 10.3109/0284186X.2014.941999. Epub 2014 Aug 20. Review.

PMID:
25140861
22.

Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma.

Crona J, Verdugo AD, Granberg D, Welin S, Stålberg P, Hellman P, Björklund P.

Endocr Connect. 2013 May 28;2(2):104-11. doi: 10.1530/EC-13-0009. Print 2013 Jun 1.

23.

Human capabilities, mild autism, deafness and the morality of embryo selection.

Jaarsma P, Welin S.

Med Health Care Philos. 2013 Nov;16(4):817-24. doi: 10.1007/s11019-013-9464-6.

PMID:
23334404
24.

Priority setting in kidney transplantation: a qualitative study evaluating Swedish practices.

Omar F, Tinghög G, Carlsson P, Omnell-Persson M, Welin S.

Scand J Public Health. 2013 Mar;41(2):206-15. doi: 10.1177/1403494812470399. Epub 2013 Jan 3.

PMID:
23287398
25.

Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre.

Crona J, Björklund P, Welin S, Kozlovacki G, Oberg K, Granberg D.

Lung Cancer. 2013 Mar;79(3):289-93. doi: 10.1016/j.lungcan.2012.12.001. Epub 2013 Jan 1.

PMID:
23286964
26.

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U.

Ann Oncol. 2013 Jan;24(1):152-60. doi: 10.1093/annonc/mds276. Epub 2012 Sep 11.

PMID:
22967994
27.

Combination chemotherapy in advanced adrenocortical carcinoma.

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group.

N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2.

28.

Living the categorical imperative: autistic perspectives on lying and truth telling-between Kant and care ethics.

Jaarsma P, Gelhaus P, Welin S.

Med Health Care Philos. 2012 Aug;15(3):271-7. doi: 10.1007/s11019-011-9363-7.

PMID:
22065242
29.

Gastric carcinoid in a patient infected with Helicobacter pylori: a new entity?

Antonodimitrakis P, Tsolakis A, Welin S, Kozlovacki G, Oberg K, Granberg D.

World J Gastroenterol. 2011 Jul 7;17(25):3066-8. doi: 10.3748/wjg.v17.i25.3066.

30.

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.

Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K.

Cancer. 2011 Oct 15;117(20):4617-22. doi: 10.1002/cncr.26124. Epub 2011 Mar 31.

31.

Autism as a natural human variation: reflections on the claims of the neurodiversity movement.

Jaarsma P, Welin S.

Health Care Anal. 2012 Mar;20(1):20-30. doi: 10.1007/s10728-011-0169-9.

PMID:
21311979
32.

Incentivizing deceased organ donation: a Swedish priority-setting perspective.

Omar F, Tinghög G, Welin S.

Scand J Public Health. 2011 Mar;39(2):156-63. doi: 10.1177/1403494810391522. Epub 2011 Jan 14.

PMID:
21239479
33.

Reply: Ethical perspectives on living donor organ transplantation in Asia.

Omar F, Welin S, Tufveson G.

Liver Transpl. 2010 Jul;16(7):917; author reply 918. doi: 10.1002/lt.22078. No abstract available.

34.

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.

Janson ET, Sørbye H, Welin S, Federspiel B, Grønbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki MJ, Oberg K, Knigge U.

Acta Oncol. 2010 Aug;49(6):740-56. doi: 10.3109/0284186X.2010.492791. Review.

PMID:
20553100
35.

Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).

Kindmark H, Janson ET, Gustavsson B, Eriksson C, Larsson G, Granberg D, Kozlowacki G, Skogseid B, Welin S, Oberg K, Eriksson B.

Acta Oncol. 2010;49(1):100-1. doi: 10.3109/02841860902897707. No abstract available.

PMID:
20100145
36.

Compensated living kidney donation: a plea for pragmatism.

Omar F, Tufveson G, Welin S.

Health Care Anal. 2010 Mar;18(1):85-101. doi: 10.1007/s10728-008-0110-z. Epub 2009 Jan 29.

PMID:
19184442
37.

Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors.

Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, Eriksson B, Janson ET.

Neuroendocrinology. 2009;89(3):302-7. doi: 10.1159/000179900. Epub 2009 Jan 29.

PMID:
19176944
38.

Selective internal radiation therapy in patients with carcinoid liver metastases.

Granberg D, Garske U, Welin S, Kindmark H, Oberg K, Eriksson B, Nyman R.

Acta Oncol. 2008;47(6):1169-71. doi: 10.1080/02841860701843738. No abstract available.

PMID:
18607860
39.

The ethics of non-heart-beating donation: how new technology can change the ethical landscape.

Zeiler K, Furberg E, Tufveson G, Welin S.

J Med Ethics. 2008 Jul;34(7):526-9. doi: 10.1136/jme.2007.021568.

40.

Profitable exchanges for scientists: the case of Swedish human embryonic stem cell research.

Persson A, Hemlin S, Welin S.

Health Care Anal. 2007 Dec;15(4):291-304. Review.

PMID:
17926128
41.

Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.

Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K, Eriksson B.

Med Oncol. 2007;24(3):330-7.

PMID:
17873310
42.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.

Clin Cancer Res. 2007 May 15;13(10):2986-91.

43.

Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors.

Granberg D, Eriksson LG, Welin S, Kindmark H, Janson ET, Skogseid B, Oberg K, Eriksson B, Nyman R.

Acta Radiol. 2007 Mar;48(2):180-5.

PMID:
17354139
44.

Some ethical problems in xenotransplantation: introductory remarks at Ethics Workshop.

Welin S, Sandrin MS.

Xenotransplantation. 2006 Nov;13(6):500-1. No abstract available.

PMID:
17059573
45.

Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.

Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET.

Neuroendocrinology. 2006;84(1):42-8. Epub 2006 Oct 12.

PMID:
17047316
46.

Gastrin-releasing-peptide in neuroendorine tumours.

Granberg D, Skogseid B, Welin S, Orlefors H, Oberg K, Wilander E.

Acta Oncol. 2006;45(1):23-7.

PMID:
16464792
47.

Carbon sequestration, the precautionary approach and the responsibility of scientists.

Buhl-Mortensen L, Myhr A, Welin S.

Water Sci Technol. 2005;52(6):205-12.

PMID:
16304953
48.

[Non-therapeutic ventilation of potential donor is ethically acceptable. It allows time to consider for both the family and the personnel].

Welin S, Sanner M, Nydahl A.

Lakartidningen. 2005 May 2-15;102(18-19):1411-2, 1414-6. Swedish.

PMID:
15929423
49.
50.

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours.

Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE, Eriksson BK.

Eur J Endocrinol. 2004 Jul;151(1):107-12.

PMID:
15248829

Supplemental Content

Support Center